Compare Gilead Sciences, Inc. (GILD) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Morgan Stanley — how do they compare? Gilead Sciences, Inc. trades at $133.02 (market cap $163.51B), while Morgan Stanley trades at $221.46 (market cap $359.28B). The key difference: Morgan Stanley is far larger — about 2.2× Gilead Sciences, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | MS | |
|---|---|---|
Market Cap | $163.51B | $359.28B |
Sector | Health | Financials |
52-Week High | $155.80 | $228.42 |
52-Week Low | $108.22 | $139.09 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Morgan Stanley (MS) trades at $228.17, up 3.2% with strong technical and fundamental momentum. The stock shows bullish technical signals with consistent earnings beats and robust revenue growth from $57.6B in 2024 to $66.0B in 2025. Recent news highlights the firm's role in leading Anthropic's IPO and expanding AI integration in wealth management, reinforcing its market position.
Outlook remains positive with analyst consensus at Buy (53.85%) and $229 price target. Key opportunities include sustained earnings growth and strategic initiatives, while risks involve volatile cash flows and high debt levels. The stock presents a balanced risk-reward profile for investors seeking financial sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
